Key players in the market are concentrating on R&D for the treatment of dermatomyositis, which is projected to fuel growth during the forecast period, according to key industry trends. For instance, in May 2022, topline results from the PRESIDIO Phase 2 clinical trial of zetomipzomib (KZR-616) in patients with dermatomyositis were released by Kezar Life Sciences, Inc., a clinical-stage biotechnology company discovering and developing ground-breaking treatments for immune-mediated and oncologic disorders (DM).
To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/5250
Impact
Key industry stakeholders were affected by the COVID-19 pandemic’s significant disruptions to clinical trial execution in the United States. Sponsors, CROs, and other drug development-related businesses have transitioned to remote working arrangements. More recently, follow-up investigations conducted in August 2020 have found that the COVID-19 pandemic continues to have an impact, with over 60% saying that the impact is average or larger.
The U.S. FDA recently stated that the impact of COVID-19 may require organisations conducting clinical trials to explore virtual patient visits or implement new processes in lieu of existing protocols. As a result, there are additional possibilities for using remote healthcare, such as running virtual or decentralised studies, using site-less clinical trials, or using other unconventional strategies that do not require in-person visits.
Inquire More Or Share Questions If Any Before The Purchase On This Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/5250
Additionally, rising dermatomyositis prevalence is anticipated to support the expansion of the worldwide dermatomyositis drug market throughout the forecast period. For instance, the National Center for Biotechnology Information reported that estimates for the incidence rates of dermatomyositis (DM) in Africa in 2020 were 7.5/1,000,000 person-years and 1.2/1,000,000 person-years, respectively.
Key Takeaways
Due to rising inorganic growth strategies by key companies for the treatment of dermatomyositis, which is anticipated to fuel market growth, the worldwide dermatomyositis medication market is anticipated to reflect a CAGR of 4.3% during the forecast period. A commercial licence option agreement for its IFN Kinoid vaccine to treat lupus and dermatomyositis in China was signed by Neovacs, a pioneer in active immunotherapy for the treatment of autoimmune diseases, and BioSense Global LLC, a biopharmaceutical company. The agreement was valued at up to €65 (US$66) million in upfront and milestone payments, excluding double-digit sales royalties.
Due to the rising hospitalisation rates linked to dermatomyositis, the hospital pharmacy segment is anticipated to have a dominating position in the worldwide dermatomyositis drug market over the forecast period. For instance, the American College of Rheumatology reported in November 2019 that a total of 160,528 individuals with a diagnosis of dermatomyositis were admitted to hospitals in the year 2019. There were 68.7% females and a mean age of 58.0 years.
Due to increased investment for dermatomyositis research, Asia Pacific is predicted to have the highest CAGR among the regions in the global dermatomyositis drug market over the forecast period. For instance, in July 2019, Jenny and Bruce Pryor donated $10 million to the Australian National University to study dermatomyositis.
F.Hoffman-La Roche Ltd., Pfizer Inc., 77Eli Lilly and Co, Teva Pharmaceuticals USA, Inc., Apotex Inc, Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd, Asahi Kasei Corporation, Zydus Cadila, Octapharma USA, and Healthcare Pharmaceuticals Limited are significant market participants in the dermatomyositis drug market.
Purchase This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/5250
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Type
- Market Snapshot, By Treatment Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Market Opportunity Map
- Report Description
- Global Dermatomyositis Market Insights
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Pipeline Analysis
- PEST Analysis
- Porter’s Five Forces Analysis
- Key Developments
- Regulatory Scenario
- Reimbursement Scenario
- Merger & Acquisition Scenario
- Brand Mapping
- Global Dermatomyositis Market – Impact of Coronavirus (Covid-19) Pandemic
- OVID-19 Epidemiology
- Impact On Supply And Demand
- Impact on Clinical Trials
- Global Dermatomyositis Market, By Type, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Adult Dermatomyositis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Dermatomyositis Sine Myositis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Juvenile (Childhood) Dermatomyositis (JDMS)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Introduction
- Global Dermatomyositis Market, By Treatment Type, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Anti-inflammatory Medication
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Immunosuppressive Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Others (Plasma Exchange, Monoclonal antibody among others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Introduction
- Global Dermatomyositis Market, By Distribution Channel, 2017 – 2030 (US$ Million)
- Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017 – 2030
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 – 2030 (US$ Million)
- Introduction
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
Email: sales@coherentmarketinsights.com
Phone: U.S.: +1-206-701-6702
U.K.: +44-020-8133-4027
JAPAN: +81-50-5539-1737
INDIA: +91-848-285-0837